ADA Scientific Sessions

From 2019 to 2024, GLP-1 prescriptions among pediatric patients with type 2 diabetes increased from 12.3% to 60.9%.

The most frequent barriers to access to glucagon include cost, patient health literacy, and insurance coverage.

Researchers explored the prevalence of obesity-related complications and obesity medication use in US children and young adults with obesity.

The initiative focuses on managing medications for high-risk diabetes patients through a collaborative drug therapy agreement.

Researchers presented an abstract describing current racial disparities in CGM access and wear time to better inform quality improvement efforts.

Researchers explored the impact of a $0 copay program on hemoglobin A1c levels in patients with type 2 diabetes who were also insured by Blue Cross and Blue Shield of Louisiana.

In a retrospective study of obesity-related mortality, researchers explored US death trends before, during, and after the COVID-19 pandemic.

Data presented at ADA 2025 showed patients who received outreach from a clinical pharmacist were more likely to be prescribed safer diabetes regimens.

In a real-world, 6-month analysis, glucagon-like peptide-1 programs with obesity telemedicine behavioral programs resulted in benefits to weight loss and blood pressure.

When compared with adults 45 years and older, those 18 to 44 years are less likely to receive treatment or achieve target goals for cardiometabolic risk factors.

Investigators assessed continuous glucose monitoring with behavioral intervention for patients with type 1 diabetes.

Data presented at ADA’s 85th Scientific Sessions showed patients who received physician education with clinical pharmacist outreach had significantly better A1c levels at 6 months compared to usual care.

Abstract researchers explored whether or not a pharmacist could serve as the lead of a diabetes coaching program, aiming to reduce medical expenditures and A1C levels for at-risk patients.

Six abstracts presented at the American Diabetes Association 84th Scientific Sessions explored how different interventions or factors can impact type 2 diabetes (T2D) management.

Three posters presented at the American Diabetes Association 84th Scientific Sessions examined GLP-1 use and cardiovascular disease risk in several different patient populations.

A pilot study presented at the American Diabetes Association 84th Scientific Sessions showed that CGM technology could produce reliable results without complications in children with leukemia/lymphoma at risk for hyperglycemia.

Three posters presented at the American Diabetes Association 84th Scientific Sessions looked into the current landscape of GLP-1s.

Research presented at the American Diabetes Association 84th Scientific Sessions suggests a population approach to CGM use could be beneficial.

Two posters presented at the American Diabetes Association 84th Scientific Sessions looked into the impact of glucagon-like peptide-1 receptor agonists in type 1 diabetes management.

Two posters presented at the American Diabetes Association 84th Scientific Sessions looked at challenges of remote CGM in older populations and after discharge from the hospital.

Two abstracts presented at the American Diabetes Association 84th Scientific Sessions explored how positive user experiences with a CGM can lead to better patient outcomes.

At the American Diabetes Association 84th Scientific Sessions, researchers presented findings from 4 studies that investigated the impact of various new diabetes technologies on managing the condition.

A selection of studies presented at the American Diabetes Association 84th Scientific Sessions examined the use of CGM technology in type 2 diabetes.

Access to diabetes self-management education and support services are crucial for improving diabetes outcomes.

Check out some of the latest research into diabetes medication options.

Kenrik Duru, MD, MSHS presented a model of future projections of Medi-Cal on Diabetes Prevention Programs through current performance measures and struggles identified.

Educating families to alleviate fear in pediatric populations regarding the flu vaccine will improve the vaccination rate and protect high-risk children. Due to the negative effects of the flu in children with diabetes, it is vital that at-risk youth be vaccinated.

Study results showed there was no significant correlation between blood glucose levels and mortality or the rate of stay in intensive care units of hospitals for sick patients with diabetes, pneumonia, and COVID-19.

At the virtual Scientific Sessions for the American Diabetes Association, Jennifer Sherr, MD, discussed the findings of a study of the Omnipod 5 automated insulin delivery system in very young children with type 1 diabetes.

An oral abstract presentation at the American Diabetes Association Virtual 81st Scientific Sessions highlighted a cardioprotective benefit of sodium-glucose co-transporter-2 inhibitors.